Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Cadrenal Therapeutics, Inc. (CVKD) had Consolidated Net Income/Loss of $-2.69M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-2.69M |
|
-- |
|
-- |
|
$2.73M |
|
$-2.73M |
|
$0.05M |
|
$-2.69M |
|
$-2.69M |
|
$-2.69M |
|
$-2.69M |
|
|
Consolidated Net Income/Loss |
$-2.69M |
$-2.69M |
|
$-2.73M |
|
$-2.73M |
|
2.04M |
|
2.04M |
|
$-1.31 |
|
$-1.31 |
|
| Balance Sheet Financials | |
$4.08M |
|
$0.01M |
|
$0.01M |
|
$4.09M |
|
$1.35M |
|
-- |
|
-- |
|
$1.35M |
|
$2.73M |
|
$2.73M |
|
$2.73M |
|
2.06M |
|
| Cash Flow Statement Financials | |
$-10.03M |
|
$-0.01M |
|
$3.88M |
|
$10.02M |
|
$3.86M |
|
$-6.16M |
|
$1.61M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-98.20% |
|
-98.20% |
|
-65.70% |
|
-98.20% |
|
$1.33 |
|
$-4.91 |
|
$-4.91 |
|